Item 7.01 Regulation FD Disclosure.

On February 1, 2013, Auxilium Pharmaceuticals, Inc. issued a press release announcing that The Journal of Urology has electronically published the uncorrected proof of the Company's pivotal IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the phase III studies that assessed XIAFLEX® (collagenase clostridium histolyticum or CCH), a novel, in-office, first-in-class biologic therapy for the potential treatment of Peyronie's disease (PD) on its website www.jurology.com.

The foregoing is qualified in its entirety by the text of the press release attached as Exhibit 99.1 hereto and incorporated herein by reference. All readers are encouraged to read the entire text of the joint press release attached hereto.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits. 99.1 Press Release, dated February 1, 2013, issued by Auxilium Pharmaceuticals, Inc.

---